April 9, 2024Open Access

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

View Full Paper

Ask AI

Bookmark

Authors

CRChristian RécherCentre National de la Recherche Scientifique CGCamille GondranCentre Hospitalier Universitaire de Toulouse PDPierre‐Yves DumasUniversité de Bordeaux

Discussion

Member takes

Implication

Registry study reveals high survival with imatinib and chemotherapy in BCR::ABL1-positive acute myeloid leukemia, suggesting this subtype should not be classified as adverse risk.

Key Points

Superior long-term survival occurred in BCR::ABL1-positive acute myeloid leukemia treated with imatinib, surpassing outcomes seen in typical adverse-risk disease.
Complete remission reached 94.4% following induction chemotherapy with imatinib, and the two-year overall survival rate was 77% across the evaluated cohort.
Analysis of registry records supports removing this entity from adverse-risk categories, as targeted tyrosine kinase inhibitors markedly improve therapeutic responses.

Cite This Study

Récher et al. (2024) studied this question.

synapsesocial.com/papers/68e6feb4b6db643587678acc https://doi.org/10.21203/rs.3.rs-4205555/v1

View Full Paper

Ask AI

Bookmark

Implication

Registry study reveals high survival with imatinib and chemotherapy in BCR::ABL1-positive acute myeloid leukemia, suggesting this subtype should not be classified as adverse risk.

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider